Resistance to epidermal growth factor receptor-targeted therapy

Drug Resistance Updates

Volumn 8, Issue 5, 2005, Pages 298-310

  Morgillo, Floriana ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; Molecular targeted cancer therapy; Monoclonal antibodies; Non small cell lung cancer; Small molecule tyrosine kinase inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BEVACIZUMAB; CARBOPLATIN; CARNETINIB; CETUXIMAB; CI 1 033; CISPLATIN; CYCLOOXYGENASE 2; CYTOKINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GENTAMICIN; IMC 225; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER; CANCER INVASION; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SENSITIVITY; DRUG TARGETING; ESOPHAGUS CANCER; GENE DELETION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARACRINE SIGNALING; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOMATIC MUTATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 27944467499     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2005.08.004     Document Type: Article

References (128)

1. T. Ahmad, G. Farnie, N.J. Bundred, and N.G. Anderson The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase J. Biol. Chem. 279 2004 1713 1719
2. M.A. Alaoui-Jamali, and H. Qiang The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery Drug Resist. Update 6 2003 95 107
3. M.L. Amador, D. Oppenheimer, S. Perea, A. Maitra, G. Cusati, C. Iacobuzio-Donahue, S.D. Baker, R. Ashfaq, C. Takimoto, A. Forastiere, and M. Hidalgo An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res. 64 2004 9139 9143
4. J. Amann, S. Kalyankrishna, P.P. Massion, J.E. Ohm, L. Girard, H. Shigematsu, M. Peyton, D. Juroske, Y. Huang, and J. Stuart Salmon Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res. 65 2005 226 235
5. C.L. Arteaga The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J. Clin. Oncol. 19 2001 32S 40S
6. R. Baserga The price of independence Exp. Cell Res. 236 1997 1 3
7. J.G. Bender, E.M. Cooney, J.J. Kandel, and D.J. Yamashiro Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Drug Resist. Update 7 2004 289 300
8. R. Bianco, I. Shin, C.A. Ritter, F.M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P.A. Dennis, G.B. Mills, and C.L. Arteaga Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822
9. A. Brunet, A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868
10. C.J. Bruns, M.T. Harbison, D.W. Davis, C.A. Portera, R. Tsan, D.J. McConkey, D.B. Evans, J.L. Abbruzzese, D.J. Hicklin, and R. Radinsky Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms Clin. Cancer Res. 6 2000 1936 1948
11. C.J. Bruns, C.C. Solorzano, M.T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky, and I.J. Fidler Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res. 60 2000 2926 2935
12. D. Busse, R.S. Doughty, T.T. Ramsey, W.E. Russell, J.O. Price, W.M. Flanagan, L.K. Shawver, and C.L. Arteaga Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity J. Biol. Chem. 275 2000 6987 6995
13. F. Cappuzzo, F.R. Hirsch, E. Rossi, S. Bartolini, G.L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, and I. Domenichini Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J. Natl. Cancer Inst. 97 2005 643 655
14. G. Carpenter Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways J. Cell Biol. 146 1999 697 702
15. Carpenter, G., 2000. EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci. STKE, PE1.
16. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res. 62 2002 200 207
17. I.W. Cheney, S.T. Neuteboom, M.T. Vaillancourt, M. Ramachandra, and R. Bookstein Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes Cancer Res. 59 1999 2318 2323
18. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, and L. Schwartz Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J. Clin. Oncol. 23 2005 1803 1810
19. F. Ciardiello, R. Bianco, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A.R. Bianco, and G. Tortora Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin. Cancer Res. 10 2004 784 793
20. F. Ciardiello, R. Bianco, V. Damiano, S. De Lorenzo, S. Pepe, S. De Placido, Z. Fan, J. Mendelsohn, A.R. Bianco, and G. Tortora Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin. Cancer Res. 5 1999 909 916
21. F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, S. De Placido, A.R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin. Cancer Res. 6 2000 3739 3747
22. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. De Placido, A.R. Bianco, and G. Tortora Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin. Cancer Res. 7 2001 1459 1465
23. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A.R. Bianco, and G. Tortora Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053 2063
24. F. Ciardiello, R. Caputo, V. Damiano, T. Troiani, D. Vitagliano, F. Carlomagno, B.M. Veneziani, G. Fontanini, A.R. Bianco, and G. Tortora Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin. Cancer Res. 9 2003 1546 1556
25. F. Ciardiello, V. Damiano, R. Bianco, C. Bianco, G. Fontanini, M. De Laurentiis, S. De Placido, J. Mendelsohn, A.R. Bianco, and G. Tortora Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A J. Natl. Cancer Inst. 88 1996 1770 1776
26. F. Ciardiello, and G. Tortora A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin. Cancer Res. 7 2001 2958 2970
27. P. Dent, D.B. Reardon, J.S. Park, G. Bowers, C. Logsdon, K. Valerie, and R. Schmidt-Ullrich Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death Mol. Biol. Cell 10 1999 2493 2506
28. J. Dong, and H.S Wiley Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains J. Biol. Chem. 275 2000 557 564
29. M.M. Eatock, A. Schatzlein, and S.B. Kaye Tumour vasculature as a target for anticancer therapy Cancer Treat. Rev. 26 2000 191 204
30. S.M. Ellerbroek, J.M. Halbleib, M. Benavidez, J.K. Warmka, E.V. Wattenberg, M.S. Stack, and L.G. Hudson Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association Cancer Res. 61 2001 1855 1861
31. H. Fan, and R. Derynck Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades EMBO J. 18 1999 6962 6972
32. Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells J. Biol. Chem. 269 1994 27595 27602
33. N. Ferrara, K. Houck, L. Jakeman, and D.W. Leung Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr. Rev. 13 1992 18 32
34. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin. Oncol. 29 2002 15 18
35. G. Fontanini, S. Vignati, L. Boldrini, S. Chine, V. Silvestri, M. Lucchi, A. Mussi, C.A. Angeletti, and G. Bevilacqua Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma Clin. Cancer Res. 3 1997 861 865
36. F.B. Furnari, H.J. Huang, and W.K. Cavenee The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells Cancer Res. 58 1998 5002 5008
37. I.E. Garcia de Palazzo, G.P. Adams, P. Sundareshan, A.J. Wong, J.R. Testa, D.D. Bigner, and L.M. Weiner Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas Cancer Res. 53 1993 3217 3220
38. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R.B. Natale, J.H. Schiller, J. Von Pawel, and A. Pluzanska Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J. Clin. Oncol. 22 2004 777 784
39. J. Gille, R.A. Swerlick, and S.W. Caughman Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation EMBO J. 16 1997 750 759
40. A.P. Gilmore, A.J. Valentijn, P. Wang, A.M. Ranger, N. Bundred, M.J. O'Hare, A. Wakeling, S.J. Korsmeyer, and C.H. Streuli Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor J. Biol. Chem. 277 2002 27643 27650
41. C.K. Goldman, J. Kim, W.L. Wong, V. King, T. Brock, and G.Y. Gillespie Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol. Biol. Cell 4 1993 121 133
42. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin. Cancer Res. 1 1995 1311 1318
43. A. Gschwind, E. Zwick, N. Prenzel, M. Leserer, and A. Ullrich Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission Oncogene 20 2001 1594 1600
44. S.W. Han, P.G. Hwang, D.H. Chung, D.W. Kim, S.A. Im, and Y.T. Kim Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer Int. J. Cancer 113 2005 109 115
45. R.B. Hazan, and L. Norton The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton J. Biol. Chem. 273 1998 9078 9084
46. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, and J.A. Reeves Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785 794
47. R.S. Herbst, D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, and E.S. Kim Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J. Clin. Oncol. 23 2005 2544 2555
48. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, A. Sandler, M.G. Kris, H.T. Tran, P. Klein, and X. Li TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J. Clin. Oncol. 23 2005 (Epub ahead of print July 25, 2005: 200502857)
49. A. Hirata, S. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res. 62 2002 2554 2560
50. F.R. Hirsch, M. Varella-Garcia, J. McCoy, H. West, A.C. Xavier, P. Gumerlock, P.A. Bunn Jr., W.A. Franklin, J. Crowley, and D.R. Gandara Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J. Clin. Oncol. 23 2005 (Epub ahead of print Jul 5, 2005: 200501282)
51. R. Humar, F.N. Kiefer, H. Berns, T.J. Resink, and E.J. Battegay Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling FASEB J. 16 2002 771 780
52. K. Inoue, J.W. Slaton, P. Perrotte, D.W. Davis, C.J. Bruns, D.J. Hicklin, D.J. McConkey, P. Sweeney, R. Radinsky, and C.P. Dinney Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin. Cancer Res. 6 2000 4874 4884
53. Y. Izumi, M. Hirata, H. Hasuwa, R. Iwamoto, T. Umata, K. Miyado, Y. Tamai, T. Kurisaki, A. Sehara-Fujisawa, S. Ohno, and E. Mekada A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor EMBO J. 17 1998 7260 7272
54. M.L. Janmaat, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin. Cancer Res. 9 2003 2316 2326
55. H.E. Jones, L. Goddard, J.M. Gee, S. Hiscox, M. Rubini, D. Barrow, J.M. Knowlden, S. Williams, A.E. Wakeling, and R.I. Nicholson Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer 11 2004 793 814
56. L.H. Kalish, R.A. Kwong, I.E. Cole, R.M. Gallagher, R.L. Sutherland, and E.A. Musgrove Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines Clin. Cancer Res. 10 2004 7764 7774
57. R.S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis 21 2000 505 515
58. K. Khamly, M. Jefford, M. Michael, and J. Zalcberg Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer Expert Opin. Investig. Drugs 14 2005 607 628
59. K. Khazaie, V. Schirrmacher, and R.B. Lichtner EGF receptor in neoplasia and metastasis Cancer Metastasis Rev. 12 1993 255 274
60. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
61. F. Koizumi, T. Shimoyama, F. Taguchi, N. Saijo, and K. Nishio Establishment of a human non-small cell lung cancer cell line resistant to gefitinib Int. J. Cancer 116 2005 36 44
62. W. Kolch, M. Calder, and D. Gilbert When kinases meet mathematics: the systems biology of MAPK signalling FEBS Lett. 579 2005 1891 1895
63. G.J. Kops, N.D. de Ruiter, A.M. De Vries-Smits, D.R. Powell, J.L. Bos, and B.M. Burgering Direct control of the Forkhead transcription factor AFX by protein kinase B Nature 398 1999 630 634
64. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 2001 2097 2106
65. C.A. Learn, T.L. Hartzell, C.J. Wikstrand, G.E. Archer, J.N. Rich, A.H. Friedman, H.S. Friedman, D.D. Bigner, and J.H. Sampson Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme Clin. Cancer Res. 10 2004 3216 3224
66. B. Li, C.M. Chang, M. Yuan, W.G. McKenna, and H.K. Shu Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas Cancer Res. 63 2003 7443 7450
67. B. Li, M. Yuan, I.A. Kim, C.M. Chang, E.J. Bernhard, and H.K. Shu Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin Oncogene 23 2004 4594 4602
68. D.M. Li, H. Sun, Y. Yuan, Q.F. Zhou, and Y.N. Cao PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cell Proc. Natl. Acad. Sci. U.S.A. 95 1998 15406 15411
69. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, and R. McCombie PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
70. B. Liu, M. Fang, Y. Lu, J. Mendelsohn, and Z. Fan Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody Oncogene 20 2001 1913 1922
71. D. Liu, J. Aguirre Ghiso, Y. Estrada, and L. Ossowski EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma Cancer Cell 1 2002 445 457
72. Y. Lu, X. Zi, and M. Pollak Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells Int. J. Cancer 108 2004 334 341
73. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J. Natl. Cancer Inst. 93 2001 1852 1857
74. D.H. Lynch, and X.D. Yang Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment Semin. Oncol. 29 2002 47 50
75. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
76. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J. Biol. Chem. 273 1998 13375 13378
77. N. Magne, J.L. Fischel, A. Dubreuil, P. Formento, M.F. Poupon, P. Laurent-Puig, and G. Milano Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br. J. Cancer 86 2002 1518 1523
78. R. Mamillapalli, N. Gavrilova, V.T. Mihaylova, L.M. Tsvetkov, H. Wu, H. Zhang, and H. Sun PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2) Curr. Biol. 11 2001 263 267
79. M.J. Marinissen, and J.S. Gutkind G-protein-coupled receptors and signaling networks: emerging paradigms Trends Pharmacol. Sci. 22 2001 368 376
80. J.L. Masferrer, K.M. Leahy, A.T. Koki, B.S. Zweifel, S.L. Settle, B.M. Woerner, D.A. Edwards, A.G. Flickinger, R.J. Moore, and K. Seibert Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res. 60 2000 1306 1311
81. R.H. Medema, G.J. Kops, J.L. Bos, and B.M. Burgering AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 Nature 404 2000 782 787
82. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
83. M.J. Merrill, and N.A. Edwards Insulin-like growth factor-I receptors in human glial tumors J. Clin. Endocrinol. Metab. 71 1990 199 209
84. J. Milanini, F. Vinals, J. Pouyssegur, and G. Pages p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts J. Biol. Chem. 273 1998 18165 18172
85. S. Modi, and A.D. Seidman An update on epidermal growth factor receptor inhibitors Curr. Oncol. Rep. 4 2002 47 55
86. L. Moro, L. Dolce, S. Cabodi, E. Bergatto, E.B. Erba, and M. Smeriglio Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines J. Biol. Chem. 277 2002 9405 9414
87. A. Morrione, G. Romano, M. Navarro, K. Reiss, B. Valentinis, M. Dews, E. Eves, M.R. Rosner, and R. Baserga Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells Cancer Res. 60 2000 2263 2272
88. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn, P.W. Zoltick, J.A. Biegel, R.L. Hayes, and A.J. Wong Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res. 55 1995 5536 5539
89. A.B. Motoyama, N.E. Hynes, and H.A. Lane The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res. 62 2002 3151 3158
90. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, and A. Cunningham Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res. 57 1997 4838 4848
91. N. Nakamura, S. Ramaswamy, F. Vazquez, S. Signoretti, M. Loda, and W.R. Sellers Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN Mol. Cell. Biol. 20 2000 8969 8982
92. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J.J. Gibbons, H. Wu, and C.L. Sawyers Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. U.S.A. 98 2001 10314 10319
93. R. O'Connor, A. Kauffmann-Zeh, Y. Liu, S. Lehar, G.I. Evan, R. Baserga, and W.A. Blattler Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis Mol. Cell. Biol. 17 1997 427 435
94. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
95. R. Pai, I.L. Szabo, B.A. Soreghan, S. Atay, H. Kawanaka, and A.S. Tarnawski PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways Biochem. Biophys. Res. Commun. 286 2001 923 928
96. Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., Varmus, H., 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (Epub Feb 2005: 2022).
97. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., Kris, M.G., Varmus, H.E., 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (Epub Jan 2005: 2025).
98. D. Peng, Z. Fan, Y. Lu, T. DeBlasio, H. Scher, and J. Mendelsohn Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145 Cancer Res. 56 1996 3666 3669
99. F. Peruzzi, M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis Mol. Cell. Biol. 19 1999 7203 7215
100. A.M. Petit, J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R.S. Kerbel Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 151 1997 1523 1530
101. K.L. Pierce, L.M. Luttrell, and R.J. Lefkowitz New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades Oncogene 20 2001 1532 1539
102. V.A. Pollack, D.M. Savage, D.A. Baker, K.E. Tsaparikos, D.E. Sloan, and J.D. Moyer Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J. Pharmacol. Exp. Ther. 291 1999 739 748
103. N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham, C. Wallasch, and A. Ullrich EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF Nature 402 1999 884 888
104. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, and N. Ferrara Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res. 57 1997 4593 4599
105. M. Prewett, P. Rockwell, R.F. Rockwell, N.A. Giorgio, J. Mendelsohn, H.I. Scher, and N.I. Goldstein The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma J. Immunother. Emphasis Tumor Immunol. 19 1996 419 427
106. D.J. Riese II, and D.F. Stern Specificity within the EGF family/ErbB receptor family signaling network Bioessays 20 1998 41 48
107. F.L. Roudabush, K.L. Pierce, S. Maudsley, K.D. Khan, and L.M. Luttrell Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells J. Biol. Chem. 275 2000 22583 22589
108. C. Sell, M. Rubini, R. Rubin, J.P. Liu, A. Efstratiadis, and R. Baserga Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor Proc. Natl. Acad. Sci. U.S.A. 90 1993 11217 11221
109. Q.B. She, D. Solit, A. Basso, and M.M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling Clin. Cancer Res. 9 2003 4340 4346
110. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, and R. Martins Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 2005 123 132
111. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
112. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272
113. P.A. Steck, M.A. Pershouse, S.A. Jasser, W.K. Yung, H. Lin, A.H. Ligon, L.A. Langford, M.L. Baumgard, T. Hattier, and T. Davis Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat. Genet. 15 1997 356 362
114. R.C. Stein Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment Endocr. Relat. Cancer 8 2001 237 248
115. S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B.E. Johnson, and P.A. Janne Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255 Cancer Res. 64 2004 7241 7244
116. M.E. Turini, and R.N. DuBois Cyclooxygenase-2: a therapeutic target Annu. Rev. Med. 53 2002 35 57
117. B.C. Turner, B.G. Haffty, L. Narayanan, J. Yuan, P.A. Havre, A.A. Gumbs, L. Kaplan, J.L. Burgaud, D. Carter, R. Baserga, and P.M. Glazer Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation Cancer Res. 57 1997 3079 3083
118. A. Ullrich, A. Gray, A.W. Tam, T. Yang-Feng, M. Tsubokawa, C. Collins, W. Henzel, T. Le Bon, S. Kathuria, and E. Chen Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity EMBO J. 5 1986 2503 2512
119. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J.M. Schlaeppi, J. Rak, and R.S. Kerbel Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res. 61 2001 5090 5101
120. A.E. Wakeling, S.P. Guy, J.R. Woodburn, S.E. Ashton, B.J. Curry, A.J. Barker, and K.H. Gibson ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res. 62 2002 5749 5754
121. C.J. Wikstrand, C.J. Reist, G.E. Archer, M.R. Zalutsky, and D.D. Bigner The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target J. Neurovirol. 4 1998 148 158
122. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol. Ther. 82 1999 241 250
123. X. Wu, M. Rubin, Z. Fan, T. DeBlasio, T. Soos, A. Koff, and J. Mendelsohn Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody Oncogene 12 1996 1397 1403
124. M.P. Wymann, and L. Pirola Structure and function of phosphoinositide 3-kinases Biochim. Biophys. Acta 1436 1998 127 150
125. F.M. Yakes, W. Chinratanalab, C.A. Ritter, W. King, S. Seelig, and C.L. Arteaga Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res. 62 2002 4132 4141
126. Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities Eur. J. Cancer 37 2001 3 S8
127. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell. Biol. 2 2001 127 137
128. K. Yu, L. Toral-Barza, C. Discafani, W.G. Zhang, J. Skotnicki, P. Frost, and J.J. Gibbons mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr. Relat. Cancer 8 2001 249 258